Tolerability and efficacy of the new uroprotective agent
ARGIMESNA was assessed within a randomized cross-over study comparing it to sodiummercaptoethanesulfonate (
MESNA), in patients treated with IFO.
MESNA i.v., 20% of IFO dose, was given to all patients before
chemotherapy; 4 h later, at random, they received
ARGIMESNA p.o., 20% of IFO dose every 2 h x 4, or
MESNA p.o., 40% of IFO dose every 4 h x 2. Overall, 78 cycles of oral uroprotection were administered: 37 for
ARGIMESNA capsules; 41 for
MESNA vials p.o.
ARGIMESNA was subjectively better tolerated, determining gastro-intestinal discomfort in only 12 out of 37 cycles versus 34/41 of
MESNA p.o. (p less than 0.001). Both preparations were equivalent for subjective and objective efficacy since no cycles were complicated by urinary symptoms (
dysuria, stranguria, or
hematuria). Nevertheless, 2 patients (7.7%) refused further oral assumption of both uroprotectors, whereas
MESNA i.v. was added in other 7 patients because of
nausea and
vomiting caused by
chemotherapy. In conclusion, this new oral preparation of mercaptoethanesulfonate turned out to be well tolerated, safe and active in the prevention of haemorrhagic
cystitis from IFO.